• Applied Use of T-5224: C-Fos/AP-1 Inhibitor for Inflammation

  2026-06-18

  T-5224 offers precise, selective inhibition of c-Fos/AP-1, advancing workflows in arthritis and cancer models. This guide details optimized protocols, troubleshooting, and the unique advantages T-5224 brings to inflammation and ferroptosis research.

• Proteoform-Specific Drug Interactions in Native Membrane Sig

  2026-06-18

  This study introduces a native top-down mass spectrometry platform to directly probe proteoform-specific drug interactions within intact cell signaling environments. The approach reveals how post-translational modifications and alternative splicing shape membrane protein pharmacology and highlights differential off-target binding of PDE5 inhibitors, including Vardenafil, to retinal PDE6 proteoforms.

• Vitamin C’s Mechanistic Power in Organoid Oncology & Virolog

  2026-06-17

  This thought-leadership article explores the mechanistic and translational potential of Vitamin C (ascorbic acid, CAS 50-81-7) as both an anticancer and antiviral agent, focusing on its applications within cutting-edge organoid platforms. Drawing on recent breakthroughs—especially the use of iPSC-derived liver, intestinal, and brain organoids for hepatitis E virus (HEV) research—this piece provides strategic guidance for translational researchers striving to bridge preclinical insights to clinical impact. It integrates high-quality evidence, protocol optimization, and competitive positioning, while highlighting how APExBIO’s high-purity Vitamin C supports reproducible, next-generation research.

• Rocilinostat (ACY-1215): HDAC6 Inhibition and Neural Develop

  2026-06-17

  Explore Rocilinostat (ACY-1215) as a selective HDAC6 inhibitor, uncovering its implications not only in multiple myeloma research but also in the context of neural development and primary cilia biology. This article uniquely bridges cancer epigenetics with neurodevelopmental mechanisms, offering advanced insights for translational research.

• MLN2238: Expanding Horizons in Proteasome β5 Subunit Inhibit

  2026-06-16

  This article offers translational researchers a mechanistic and strategic roadmap for leveraging MLN2238—a next-generation proteasome β5 subunit inhibitor—across the continuum of oncology and protein homeostasis research. Connecting new insights from the ROS/JNK/CREB axis to actionable workflows in multiple myeloma and lymphoma models, it outlines how MLN2238 from APExBIO enables research advances beyond conventional paradigms. The article integrates key numeric claims, protocol guidance, and evidence-backed analysis, culminating in an outlook on future research frontiers.

• Tamsulosin Improves Ureteral Stone Passage: Meta-Analysis In

  2026-06-16

  This systematic review and meta-analysis resolves conflicting evidence regarding Tamsulosin's role in facilitating symptomatic ureteral stone expulsion. By synthesizing data from 49 studies, the authors demonstrate significant improvements in stone clearance rates and expulsion time, with no increase in adverse effects—highlighting practical implications for urological research and clinical protocols.

• Differentiating ACE Inhibitors: Pharmacokinetics and Researc

  2026-06-15

  Piepho's overview delineates the structural and pharmacokinetic diversity among ACE inhibitors, with a focus on how these differences influence their application in hypertension and cardiovascular research. The paper highlights the unique position of phosphinic acid ACE inhibitors, such as fosinopril, in translational models due to their dual renal-hepatic elimination and favorable pharmacodynamic properties.

• Linezolid: Oxazolidinone Antimicrobial Advances in Resistanc

  2026-06-15

  Linezolid is a gold-standard oxazolidinone antimicrobial for dissecting Gram-positive resistance, streamlining workflows from MRSA modeling to translational bacterial pneumonia research. This article delivers actionable protocols, comparative insights, and troubleshooting guidance for maximizing research reproducibility and impact.

• Deracoxib and Piroxicam Synergy in Canine Mammary Tumor Cell

  2026-06-14

  This study systematically evaluated the antiproliferative and pro-apoptotic effects of Deracoxib, a selective COX-2 inhibitor, alone and in combination with piroxicam on canine mammary carcinoma cells. The combination therapy demonstrated enhanced cytotoxicity and apoptosis induction at lower concentrations, highlighting potential translational strategies for canine cancer therapy and mechanistic cancer biology research.

• AMH–SMAD4 Axis Regulates Granulosa Cell Fate in PCOS Rats

  2026-06-13

  This study clarifies how anti-Müllerian hormone (AMH) modulates granulosa cell proliferation and apoptosis in a PCOS rat model via SMAD4 signaling. By integrating protein expression analysis and functional assays, the research provides mechanistic insight into follicular dysregulation in PCOS and informs future strategies for targeted intervention.

• Telmisartan as a Precision Tool for Decoding Cardiac Hypertr

  2026-06-12

  Explore the advanced use of Telmisartan, a potent angiotensin II receptor antagonist, in cardiovascular disease research. This article uniquely dissects its mechanistic roles and practical applications in unraveling cardiac hypertrophy signaling, offering nuanced insights beyond conventional protocols.

• PR-619 in Epigenetic and Immunological Ubiquitination Resear

  2026-06-12

  Explore how PR-619, a deubiquitylating enzymes inhibitor, uniquely advances ubiquitination pathway research at the intersection of epigenetics and immuno-oncology. This article delivers deeper insight into assay design and translational implications, setting it apart from standard protocol guides.

• Telmisartan as a Precision Tool for Cardiac Hypertrophy Sign

  2026-06-11

  Explore Telmisartan, a potent angiotensin II receptor antagonist, as a precision research tool in cardiovascular disease. This article reveals unique insights into its role in dissecting JAK2/STAT3 and NF-κB pathways in cardiac hypertrophy, setting it apart from existing studies.

• Spatially Concentrated Adenine Base Editing of PLP1 in Oligo

  2026-06-11

  This study introduces a spatially concentrated adenine base editor (cABE-2.0) to efficiently correct pathogenic PLP1 mutations in oligodendrocytes, addressing the genetic basis of Pelizaeus–Merzbacher disease. By leveraging targeted nuclear localization and phase separation, the approach enhances editing efficiency and fidelity, offering a new gene therapy framework for myelin disorders.

• Tetrazolium (chloride): Precision in Tissue Viability and Is

  2026-06-10

  Tetrazolium (chloride) (TTC, Tetrazolium Red) empowers researchers to map mitochondrial function and tissue viability with quantitative rigor, especially in ischemic injury models. Its robust reduction chemistry and clear readout differentiate it from generic cell viability dyes, enabling translational insights and reproducible outcomes across preclinical workflows.

449 records 14/30 page Previous Next First page 上5页 1112131415 下5页 Last page